| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | selumetinib:JQ-1 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.0067 | 1 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.006 | 1 |